The world's first mRNA vaccine against a deadly disease

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

The world's first mRNA vaccine against a deadly disease

Latest News

Two Symptoms Linked to Antibiotic Delays in Presumed Sepsis

Exercise and Cancer Survival; COVID Vaccine and Immune Checkpoint Inhibitors

BPAP Intervention Flops in Asthma Study

To Face Scrutiny at ESC: Statins for the Elderly, New Heart Attack Therapies

Radio Silence on Mitch McConnell's Health Persists

Cefepime Tied to Higher Mortality Odds vs Other Beta-Lactams

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Todays Updates

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

Latest News

News All Time

Discordant Tissue Findings in Suspected HLH

What Extreme Athletes Teach Us About Sleep Deprivation

Omalizumab May Ease Inflammation in Chronic Urticaria

Pediatric Lung Transplantation Enters a New Era

CVS Health's Aetna to Streamline Cancer Treatment Approvals

Diphtheria Debate Exposes Health Misinformation

Azithromycin Use Cuts Cesarean Infections

Methotrexate for IBD: How Do GIs Use It?

AI Digital Twins Get Better and Better: Cancer in Crosshairs

S1P Modulators: 5 Agents, One Safety Playbook

As-Needed Allergic Rhinitis Meds Comparable to Daily Use

Host-Directed Therapies and Phages in Lung Care

Mild Brain Injury Frequently Missed in the ED

D10 Matches D50 for Hypoglycemia, Shows Lower Rebound Risk

A Rare Hearing Implant Bypasses Damaged Nerves

Two-Midnight Rule: Key Strategies for Observation Patients

Recommended News For You

In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

Inconclusive BRCA Results Linked to Higher BC Risk

Pain’s Toll: Frailty Risk for Childhood Cancer Survivors

Recommended Articles For You

Exploring New Solutions for MCV Low: Unlocking the Potential for Improved Health

Cemiplimab: A Revolutionary Drug For Treating Cancer

The Ins and Outs of Glossectomy: What You Need to Know

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.